Delivery Order SPE2DB20D2104-SPE2DB25FMXWR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,392.69 to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Linzess 290 microgram capsules (30-count unit dose). This is a firm fixed price, competitive delivery order with no set-aside designation and an ultimate completion date of August 11, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Linzess 290mg capsules (30-count) with a ceiling value of $1,932.27. This firm fixed-price delivery order is non-competitive and is scheduled for completion by September 4, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $1,064.49 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Linzess 72 mg capsules in a 30-count unit pack, with a contract ceiling value of $1,495.59 and an ultimate completion date of July 21, 2025. This firm fixed price delivery order represents a non-competitive award and is classified as a child contract under AmerisourceBergen's larger federal contracting framework. The performance location is the company's corporate office in...
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,333.53 to AmerisourceBergen Drug Corp for Linzess 72 mcg capsules (30-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order was performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competed among all eligible vendors in the open market. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Linzess 72 mcg capsules (quantity: 30 units) valued at $2,112.00. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract has an ultimate completion date of July 25, 2025. This...
- The Defense Logistics Agency awarded a delivery order valued at $10,909.98 to AmerisourceBergen Drug Corp for LINZESS 72 mcg capsules (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Linzess 145 microgram capsules (30-count unit of use packaging) with a ceiling value of $1,676.80. This firm fixed-price delivery order, which is not set-aside for any designated small business category, is scheduled for completion by August 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $2,386.99 for the supply of Linzess 145 mcg capsules (30-unit quantity) with an ultimate completion date of August 5, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXWRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Linzess 72 microgram capsules (30-count unit of use packaging) with a ceiling value of $1,155.69. This firm fixed-price delivery order, which is expected to be completed by August 15, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables comprehensive pharmaceutical support for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio under its DLA contract encompasses specialty medications, brand-name and generic pharmaceuticals, vaccines, and specialized medical supplies across multiple therapeutic domains. This particular delivery order for Linzess, a prescription medication used to treat irritable bowel syndrome and chronic idiopathic constipation, reflects the company's ongoing role in supplying essential pharmaceutical commodities to support military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 8/14/25 |